Alexion Pharma (ALXN): 5 Reasons Its A Top Large Cap Pick - Piper Jaffray

August 16, 2016 8:22 AM EDT
Get Alerts ALXN Hot Sheet
Price: $130.84 +3.84%

Rating Summary:
    21 Buy, 9 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 19 | Down: 33 | New: 11
Trade ALXN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Piper Jaffray analyst, Joshua Schimmer, reiterated his Overweight rating on shares of Alexion Pharmaceuticals (NASDAQ: ALXN) and noted that the company remains one of his top large cap picks for 5 reasons:

1) Soliris and its next-gen versions will be more difficult to displace than many investors believe

2) the Myasthenia Gravis indication will be added to labels in 2017

3) the company's unique expertise in complement inhibition will deliver additional pipeline shots on goal

4) the company will continue to diversify its portfolio away from Soliris and continue its strong metabolic franchise launch

5) potentially transformational pipeline programs advance through clinical development.

No change to the price target of $185.

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $136.07 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

Piper Jaffray, Joshua Schimmer

Add Your Comment